Heartland Advisors Inc. Invests $15.35 Million in The Cooper Companies, Inc. $COO

Heartland Advisors Inc. acquired a new position in The Cooper Companies, Inc. (NASDAQ:COO) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 187,263 shares of the medical device company’s stock, valued at approximately $15,348,000.

Several other large investors have also recently made changes to their positions in the stock. Capital World Investors lifted its holdings in shares of Cooper Companies by 25.7% in the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after acquiring an additional 2,159,233 shares during the last quarter. State Street Corp lifted its holdings in shares of Cooper Companies by 1.2% in the 2nd quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after acquiring an additional 104,910 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Cooper Companies by 332.9% in the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after acquiring an additional 4,756,178 shares during the last quarter. Sustainable Growth Advisers LP lifted its holdings in shares of Cooper Companies by 22.1% in the 3rd quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock worth $283,327,000 after acquiring an additional 747,476 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Cooper Companies by 108.2% in the 4th quarter. Franklin Resources Inc. now owns 4,022,033 shares of the medical device company’s stock worth $329,646,000 after acquiring an additional 2,089,763 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Recent commentary highlighted The Cooper Companies as a strong long-term growth name, with Zacks calling it a top growth stock and Seeking Alpha noting potential for an analyst upgrade as valuation improves. Article Title
• Positive Sentiment: Analysts and market commentary also pointed to the company’s demand growth and prior quarterly earnings beat, which can reinforce confidence in revenue momentum. Article Title
• Neutral Sentiment: One article noted that Cooper has strong revenue growth, especially in CooperVision, but also said litigation charges tied to embryo culture media recalls have weighed on reported profitability; these issues do not appear to change the long-term outlook materially. Article Title
• Negative Sentiment: Some analysis still argues The Cooper Companies needs stronger return on equity and profit margins, which may temper enthusiasm despite solid sales trends. Article Title

Cooper Companies Price Performance

Cooper Companies stock opened at $67.69 on Thursday. The firm has a market cap of $13.20 billion, a PE ratio of 57.36, a price-to-earnings-growth ratio of 1.80 and a beta of 0.87. The Cooper Companies, Inc. has a 52-week low of $58.89 and a 52-week high of $89.83. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The company’s 50 day moving average is $64.94 and its two-hundred day moving average is $74.45.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. On average, research analysts expect that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on COO shares. Stifel Nicolaus decreased their price objective on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. BNP Paribas Exane reduced their target price on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Wells Fargo & Company reiterated a “sell” rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $82.64.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.